网友：新一代荨麻疹创新药瑞米布替尼片（瑞普多），这个药怎么样？京东给发的广告，我搜了信息不多。

Sept. 30, 2025 -- Novartis announced today that Rhapsido® (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment.